반응식
Cl.[CH3:2][S:3]([C:6]1[CH:11]=[CH:10][C:9]([N:12]2[C:16]3=[N:17][CH:18]=[N:19][C:20]([O:21][CH:22]4[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]4)=[C:15]3[CH:14]=[N:13]2)=[CH:8][CH:7]=1)(=[O:5])=[O:4].CCN(CC)CC.[CH2:35]([C:37]([CH2:39]Br)=[O:38])[CH3:36].C(O)(C(F)(F)F)=O>O1CCOCC1.CC#N.O>[CH3:2][S:3]([C:6]1[CH:11]=[CH:10][C:9]([N:12]2[C:16]3=[N:17][CH:18]=[N:19][C:20]([O:21][CH:22]4[CH2:27][CH2:26][N:25]([CH2:39][C:37](=[O:38])[CH2:35][CH3:36])[CH2:24][CH2:23]4)=[C:15]3[CH:14]=[N:13]2)=[CH:8][CH:7]=1)(=[O:4])=[O:5]참가 물질
반응물 4
생성물 1
시약·촉매·용매 3
반응 조건
- 온도
- 100 °C
실험 절차
To a solution of 1-(4-methanesulfonyl-phenyl)-4-(piperidin-4-yloxy)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride (30.0 mg, 0.073 m mmol) and Et3N (35 μL) in dioxane (1.5 mL) was added bromomethyl ethyl ketone (22 μL, 0.219 mmol). The mixture was heated by microwave irradiation at 100° C. for 10 min. The mixture was diluted with CH3CN (3 mL) and purified by reverse-phase HPLC: Phenomenex® Luna C18 column (10μ, 250×21.2 mm), 5% (v/v) CH3CN (containing 1% v/v TFA) in H2O (containing 1% v/v TFA) gradient to 95% H2O, 20 mL/min, λ=214 nm to give Compound A168 (7.8 mg, 0.014 mmol, 19% yield) isolated as a white solid. HPLC/MS: Alltech® Prevail C18 column (5μ, 50×4.6 mm), 5% v/v CH3CN (containing 1% v/v TFA) in H2O (containing 1% v/v TFA) gradient to 99% v/v CH3CN in H2O, 3.5 mL/min, tr=1.69 min, ESI+=444.3 (M+H).
후처리
- custompurified by reverse-phase HPLC
- additionPhenomenex® Luna C18 column (10μ, 250×21.2 mm), 5% (v/v) CH3CN (containing 1% v/v TFA) in H2O (
- additioncontaining 1% v/v TFA) gradient to 95% H2O, 20 mL/min, λ=214 nm
- customto give Compound A168 (7.8 mg, 0.014 mmol, 19% yield)
- customisolated as a white solid
출처 및 근거
- ORD 기록
- ord-04371e20a23f4e7b80a74606a1d3abcf
- 출처 데이터셋
- uspto-grants-2006_11
- 특허 번호
- US07132426B2
연결된 노트
불러오는 중…